COMPARISON OF THE CHROMOGENIC AND ONE-STAGE ASSAYS FOR FACTOR IX
因子 IX 显色法和一阶段法的比较
基本信息
- 批准号:3804918
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
The one-stage clotting assay is the basis for the most widely used
method for determining factor IX activity. It is based on the
correction of the clotting time of fIX deficient plasma by the addition
of fIX. Recently, a new assay for fIX has been developed that assay
involves the addition of fIX to a preparation of fXIa and fX. The
amount of fIX added can be determined from the rate of cleavage of a
chromogenic substrate by factor Xa. We have undertaken a formal
comparison of the clotting and chromogenic assays for determining
potency of factor IX concentrates. Multiple comparisons of the assays
using CBER's current fIX standard, FN2 versus the current WHO standard,
84/618, demonstrated equivalence of the two methods. The value of FN2
by clotting assay was 9.3 and 9.1 for the chromogenic assay.
Comparisons of multiple lots of factor IX concentrates submitted to CBER
for testing indicated significant disagreement between the methods for
some concentrates. This disagreement could be somewhat reduced when the
chromogenic assay was read kinetically rather than using the endpoint
method. Further comparative studies are in progress.
一级凝血试验是目前应用最广泛的基础
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
W FRICKE其他文献
W FRICKE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('W FRICKE', 18)}}的其他基金
ACTIVATION OF FVIII BY FXA AND INHIBITION BY TISSUE FACTOR PATHWAY INHIBITOR
FXA 对 FVIII 的激活和组织因子途径抑制剂的抑制
- 批准号:
3804919 - 财政年份:
- 资助金额:
-- - 项目类别:
EPITOPE MAPPING OF FACTOR VIII AND VON WILLEBRAND FACTOR
因子 VIII 和冯·维勒布兰德因子的表位作图
- 批准号:
3770445 - 财政年份:
- 资助金额:
-- - 项目类别:
CHARACTERIZATION OF THE FACTOR VIII IN FACTOR VIII CONCENTRATES
因子 VIII 浓缩物中因子 VIII 的表征
- 批准号:
3792653 - 财政年份:
- 资助金额:
-- - 项目类别:
HIV INFECTION DUE TO CLOTTING FACTOR CONCENTRATES--RESULTS OF THE SSP
浓缩凝血因子引起的 HIV 感染——SSP 结果
- 批准号:
3792655 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
Activation peptide of coagulation factor IX protects vascular endothelial cells
凝血因子IX激活肽对血管内皮细胞的保护作用
- 批准号:
21K08380 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
The function of activation peptide of coagulation factor IX
凝血因子IX激活肽的功能
- 批准号:
17K10850 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Induction of hypoxic tolerance by activation peptide of blood coagulation factor IX
凝血因子IX激活肽诱导缺氧耐受
- 批准号:
17K17069 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Young Scientists (B)